FI75738C - Parenteralt vätskeadministreringssystem. - Google Patents
Parenteralt vätskeadministreringssystem. Download PDFInfo
- Publication number
- FI75738C FI75738C FI822654A FI822654A FI75738C FI 75738 C FI75738 C FI 75738C FI 822654 A FI822654 A FI 822654A FI 822654 A FI822654 A FI 822654A FI 75738 C FI75738 C FI 75738C
- Authority
- FI
- Finland
- Prior art keywords
- fluid
- chamber
- drug
- primary
- container
- Prior art date
Links
- 239000012530 fluid Substances 0.000 title claims description 156
- 238000002156 mixing Methods 0.000 claims description 81
- 239000007788 liquid Substances 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 12
- 238000004891 communication Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 description 152
- 229940079593 drug Drugs 0.000 description 119
- 239000000243 solution Substances 0.000 description 33
- 238000002560 therapeutic procedure Methods 0.000 description 30
- 229940124597 therapeutic agent Drugs 0.000 description 28
- 239000000126 substance Substances 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 20
- 239000000835 fiber Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 239000003978 infusion fluid Substances 0.000 description 15
- 230000003204 osmotic effect Effects 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 12
- 238000012377 drug delivery Methods 0.000 description 11
- 239000011521 glass Substances 0.000 description 10
- 239000012510 hollow fiber Substances 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 229920001971 elastomer Polymers 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229920002301 cellulose acetate Polymers 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920000098 polyolefin Polymers 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012780 transparent material Substances 0.000 description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- 229920001747 Cellulose diacetate Polymers 0.000 description 2
- 229920002284 Cellulose triacetate Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- 238000002074 melt spinning Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000012229 microporous material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- HBGALFVDRUBTCE-UHFFFAOYSA-N 1,2-dichloroethane;propan-2-one Chemical compound CC(C)=O.ClCCCl HBGALFVDRUBTCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920006238 degradable plastic Polymers 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001855 polyketal Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Claims (2)
1. Parenteralt vätskeadministreringssystem (10) med a) en primärbehlllare (62) för en farmaceutiskt godtagbar vätska (63), b) en primär droppkammare (69) i vätskekommunikation med pri-märbehallaren och med vilken man kan reglera strömnings-hastigheten för den vätska som kommer fran primärbehalla-ren, c) en sekundärbehallare (76) för en farmaceutiskt godtagbar vätska (78) och d) en sekundär droppkammare (83) i vätskekommunikation med sekundärbehallaren och med vilken man kan reglera ström-ningshastigheten för den vätska som kommer fran sekundärbehallaren, och vilket ärkännetecknat därav, att den uppvisar en sekundär blandningskammare (87, 133) som är i vätskekommunikation med den sekundära droppkammaren (83) och/eller en primär blandningskammare (110, 152), som är i vätskekommunikation med den primära droppkammaren (69), varvid de sekundära och primära blandningskamrarna (87, 133, 110, 152) är försedda med utlopp (114) och blandningskamrarna är sadana att de är avsedda att innehalla ett eller flera behandlings-medel (207, 283) i fast form sa att den fran droppkammaren till blandningskammaren ingaende vätskan (63 och/eller 78) kan bilda med behandlingsmedlet (-medlen) en behandlingsme-delslösning, som avgar genom ett membran (208) eller nagon annat strömningsreglerande distributionsanordning (279) genom utloppet, och att utloppsrören (138, 155) fran utgangen av blandningskamrarna (133, 152) eller utloppsrören (72, 91) fran utgangen av droppkammaren (69) är förenade till ett ge-mensamt rör (74, 141) som är försett med en kanyl (75, 142).
2. Administreringssystem i enlighet med patentkravet 1, k ä n-netecknat därav, att membranet är av ett polymerma-terial.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28908281A | 1981-07-31 | 1981-07-31 | |
| US28908281 | 1981-07-31 | ||
| US06/310,047 US4511353A (en) | 1981-07-13 | 1981-10-09 | Intravenous system for delivering a beneficial agent |
| US31004781 | 1981-10-09 | ||
| US06/312,491 US4552555A (en) | 1981-07-31 | 1981-10-19 | System for intravenous delivery of a beneficial agent |
| US31249181 | 1981-10-19 | ||
| US06/325,206 US4432756A (en) | 1981-11-27 | 1981-11-27 | Parenteral controlled therapy |
| US32520681 | 1981-11-27 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI822654A0 FI822654A0 (fi) | 1982-07-29 |
| FI822654L FI822654L (fi) | 1983-02-01 |
| FI75738B FI75738B (fi) | 1988-04-29 |
| FI75738C true FI75738C (sv) | 1988-08-08 |
Family
ID=27501494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI822654A FI75738C (sv) | 1981-07-31 | 1982-07-29 | Parenteralt vätskeadministreringssystem. |
Country Status (20)
| Country | Link |
|---|---|
| AT (1) | AT392005B (sv) |
| AU (1) | AU560242B2 (sv) |
| CA (1) | CA1173795A (sv) |
| CH (1) | CH659775A5 (sv) |
| DE (1) | DE3228595A1 (sv) |
| DK (1) | DK159379C (sv) |
| ES (1) | ES514598A0 (sv) |
| FI (1) | FI75738C (sv) |
| FR (1) | FR2510413B1 (sv) |
| GB (1) | GB2107191B (sv) |
| GR (1) | GR76223B (sv) |
| IE (1) | IE53549B1 (sv) |
| IL (1) | IL66400A (sv) |
| IT (1) | IT1212664B (sv) |
| MX (2) | MX158878A (sv) |
| NL (1) | NL191282C (sv) |
| NO (1) | NO153554C (sv) |
| NZ (1) | NZ201330A (sv) |
| PT (1) | PT75300B (sv) |
| SE (1) | SE462365B (sv) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4576592A (en) * | 1983-03-30 | 1986-03-18 | Anatros Corporation | Dual source parenteral infusion apparatus |
| US4695272A (en) * | 1984-10-26 | 1987-09-22 | Aktiebolaget Hassle | Drug release device |
| JPS62501057A (ja) | 1984-12-03 | 1987-04-30 | バクスタ−、インタ−ナショナル、インコ−ポレイテッド | 有益な剤と希釈剤との受動的混合を可能とするハウジング |
| DE3585530D1 (de) * | 1984-12-03 | 1992-04-09 | Baxter Int | Verabreichungsanordnung fuer arzneimittel zum vorbeugen lokaler und systemischer toxizitaet. |
| US4874366A (en) * | 1984-12-03 | 1989-10-17 | Baxter Internatiional Inc. | Housing enabling passive mixing of a beneficial agent with a diluent |
| US4715850A (en) * | 1984-12-06 | 1987-12-29 | Controlled Release Technologies, Inc. | Therapeutic agent delivery system and method |
| US4952210A (en) * | 1985-12-13 | 1990-08-28 | Becton, Dickinson And Company | Parenteral fluid administration set |
| US4772273A (en) * | 1985-12-13 | 1988-09-20 | Becton, Dickinson And Company | Variable-volume vented container |
| WO1989004689A1 (en) * | 1987-11-16 | 1989-06-01 | Baxter International Inc. | Glassy matrix for administration of beneficial agent |
| US4978337A (en) * | 1988-09-08 | 1990-12-18 | Alza Corporation | Formulation chamber with exterior electrotransport delivery device |
| AU634227B2 (en) * | 1989-05-01 | 1993-02-18 | Baxter International Inc. | Composition of beneficial agent and method for administering the same by controlled dissolution |
| US5116316A (en) * | 1991-02-25 | 1992-05-26 | Baxter International Inc. | Automatic in-line reconstitution system |
| US6288027B1 (en) | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| US6610832B1 (en) | 1995-03-23 | 2003-08-26 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| DE19757224A1 (de) | 1997-12-22 | 1999-07-01 | Bayer Ag | Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation |
| CA2444590C (en) | 2001-04-18 | 2009-12-01 | Robert L. Mcginnis | Stabilized hemoglobin solutions |
| DE20218624U1 (de) | 2002-12-02 | 2003-04-03 | Maco Pharma International GmbH, 63225 Langen | Schlauch-Filter-Set zur aseptischen Herstellung von Parenteralia |
| WO2007087570A2 (en) | 2006-01-24 | 2007-08-02 | Northfield Laboratories, Inc. | Polymerized hemoglobin media and its use in isolation and transplantation of islet cells |
| DE102007046951B3 (de) * | 2007-10-01 | 2009-02-26 | B. Braun Melsungen Ag | Vorrichtung zum Einführen eines Medikaments in einen Infusionsbehälter |
| US10426943B2 (en) | 2011-08-11 | 2019-10-01 | Attwill Medical Solutions Sterilflow L.P. | Insert for luer connection |
| WO2015179548A2 (en) | 2014-05-21 | 2015-11-26 | Attwill Medical Solutions Steriflow L.P. | Insert for catheter system |
| ES2671844B1 (es) | 2015-06-11 | 2019-03-22 | Attwill Medical Solutions Inc | Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina. |
| WO2025221761A2 (en) * | 2024-04-17 | 2025-10-23 | Genzyme Corporation | Medicament container and kit for reconstituting a lyophilized medicament |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE7408746U (de) * | 1974-07-11 | Weissinger H | Infusions-Gerät zur elektronischen Überwachung für medizinische Zwecke | |
| CH114187A (de) * | 1924-11-07 | 1926-03-01 | Oskar Heublein Wilhelm | Ampulle für Injektionsflüssigkeiten. |
| US3305446A (en) * | 1963-01-07 | 1967-02-21 | Baxter Laboratories Inc | Method of preparing parenteral solution |
| CH497181A (fr) * | 1964-05-13 | 1970-10-15 | Vifor Sa | Appareil pour l'infusion de liquides dans un corps |
| US3993073A (en) * | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3845480A (en) * | 1973-02-20 | 1974-10-29 | Air Technologies Inc | Particulate detector system |
| US3982534A (en) * | 1975-01-10 | 1976-09-28 | Buckman Thomas P | Intravenous administration system |
| US4034754A (en) * | 1975-08-07 | 1977-07-12 | Baxter Travenol Laboratories, Inc. | Intravenous solution set having a constricted inner diameter portion |
| DE2721752C2 (de) * | 1977-05-13 | 1983-12-29 | Siemens AG, 1000 Berlin und 8000 München | In einen menschlichen oder tierischen Körper implantierbares Gerät zur Infusion einer medizinischen Flüssigkeit |
| EP0005606A1 (en) * | 1978-05-12 | 1979-11-28 | Vishnu Shanker Shukla | Improvements in and relating to apparatus for administering intravenous drugs |
| US4235236A (en) * | 1979-02-12 | 1980-11-25 | Alza Corporation | Device for dispensing drug by combined diffusional and osmotic operations |
| US4256104A (en) * | 1979-02-28 | 1981-03-17 | Abbott Laboratories | Equipment sets and system for the sequential administration of medical liquids at dual flow rates |
| AU6249180A (en) * | 1979-09-18 | 1981-04-09 | Millipore Corp. | Automatic dual rate i.v. administration |
-
1982
- 1982-07-20 NZ NZ201330A patent/NZ201330A/en unknown
- 1982-07-20 GB GB08220968A patent/GB2107191B/en not_active Expired
- 1982-07-20 GR GR68803A patent/GR76223B/el unknown
- 1982-07-22 PT PT75300A patent/PT75300B/pt unknown
- 1982-07-26 IL IL66400A patent/IL66400A/xx not_active IP Right Cessation
- 1982-07-26 NO NO822558A patent/NO153554C/no not_active IP Right Cessation
- 1982-07-27 NL NL8203004A patent/NL191282C/xx not_active IP Right Cessation
- 1982-07-28 AU AU86519/82A patent/AU560242B2/en not_active Expired
- 1982-07-29 SE SE8204503A patent/SE462365B/sv not_active IP Right Cessation
- 1982-07-29 CA CA000408396A patent/CA1173795A/en not_active Expired
- 1982-07-29 FI FI822654A patent/FI75738C/sv not_active IP Right Cessation
- 1982-07-30 DK DK340982A patent/DK159379C/da active
- 1982-07-30 ES ES514598A patent/ES514598A0/es active Granted
- 1982-07-30 MX MX202371A patent/MX158878A/es unknown
- 1982-07-30 DE DE19823228595 patent/DE3228595A1/de active Granted
- 1982-07-30 IT IT8267970A patent/IT1212664B/it active
- 1982-07-30 IE IE1845/82A patent/IE53549B1/en not_active IP Right Cessation
- 1982-07-30 CH CH4634/82A patent/CH659775A5/de not_active IP Right Cessation
- 1982-07-30 AT AT0295482A patent/AT392005B/de not_active IP Right Cessation
- 1982-07-30 MX MX193838A patent/MX152158A/es unknown
- 1982-08-02 FR FR8213456A patent/FR2510413B1/fr not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI75738C (sv) | Parenteralt vätskeadministreringssystem. | |
| US4985017A (en) | Parenteral therapeutical system comprising drug cell | |
| US4439183A (en) | Parenteral agent dispensing equipment | |
| US4548598A (en) | Parenteral agent dispensing equipment | |
| US5069671A (en) | Intravenous medication | |
| US4424056A (en) | Parenteral administration | |
| US4740103A (en) | Intravenous system for delivering a beneficial agent | |
| US4994031A (en) | Intravenous system for delivering a beneficial agent | |
| US4740200A (en) | Intravenous system for delivering a beneficial agent | |
| US4432754A (en) | Apparatus for parenteral infusion of fluid containing beneficial agent | |
| IE52601B1 (en) | Drug administration device | |
| US4479794A (en) | System for intravenous therapy | |
| EP0162531B1 (en) | Parenteral delivery system utilizing a hollow fibre cellular unit | |
| USRE34365E (en) | Intravenous system for delivering a beneficial agent | |
| US4973307A (en) | Method for administering drugs to a patient | |
| US4479793A (en) | Parenteral administration using drug delivery device | |
| US4740198A (en) | Method of administering intravenous drug using rate-controlled dosage form | |
| US4484909A (en) | Parenteral therapy using solid drug | |
| US4740201A (en) | Intravenous system for delivering a beneficial agent | |
| US4586922A (en) | Intravenous system for delivering a beneficial agent | |
| US4548599A (en) | Parenteral controlled therapy | |
| US4515585A (en) | System for parenteral administration of agent | |
| US4521211A (en) | Parenteral agent dispensing equipment | |
| US4790820A (en) | Parenteral agent dispensing equipment with drug releasing member | |
| US4525162A (en) | Parenteral controlled delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |
Owner name: ALZA CORPORATION |